When and Where Does LGSOC Start?

Dr. Kwong-Kwok Wong (K.K. Wong), PhD examines the origins of LGSOC (low-grade serous ovarian cancer) and the progression of borderline ovarian tumors into invasive disease, and why catching that transition early is so critical to improving outcomes for patients. Unlike high-grade serous ovarian cancer, LGSOC grows slowly, resists standard chemotherapy, and disproportionately affects younger women. Research has identified a distinct genetic profile — including MAP Kinase pathway mutations in roughly 60% of cases — that sets it apart and opens the door for targeted therapies. Not These Ovaries funds exactly this kind of foundational science. Key facts: - LGSOC represents approximately 2–4% of all epithelial ovarian cancer cases - Up to 20% of women with advanced borderline tumors may develop LGSOC over their lifetime - Patients are diagnosed roughly 20 years younger on average than those with high-grade disease - There are currently no FDA-approved treatments specifically for LGSOC or borderline ovarian tumors For more information and resources for women with LGSOC, visit https://www.nottheseovaries.org/ #LGSOC #LowGradeSerousOvarianCancer #BorderlineOvarianTumor #OvarianCancer #OvarianCancerResearch #OvarianCancerAwareness #NotTheseOvaries #FundTheCure #CancerResearch #WomensHealth